Search Within

Early Drug Development Service

Formats
  1. Meeting Abstract (234)
  2. Journal Article (209)
  3. Review (7)
  4. Editorial (5)
  5. Research Letter (3)
  6. Miscellaneous (2)
  7. Book Section (1)
Groups
  1. Department of Medicine (461)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (244)
  4. Department of Pathology and Laboratory Medicine (200)
  5. Human Oncology and Pathogenesis Program (193)
  6. Gynecologic Medicine Service (186)

More Groups

People
  1. David Hyman (354)
  2. Alison Schram (123)
  3. Alexander Drilon (111)
  4. Michael Berger (111)
  5. David Solit (110)
  6. Marc Ladanyi (91)

More People

Years
  1. 2025 (6)
  2. 2024 (29)
  3. 2023 (18)
  4. 2022 (27)
  5. 2021 (27)
  6. 2020 (49)

More Years

Publications
  1. Journal of Clinical Oncology (111)
  2. Annals of Oncology (38)
  3. Cancer Research (37)
  4. Clinical Cancer Research (33)
  5. Cancer Discovery (23)
  6. Blood (21)

More Publications

Publishers
  1. American Society of Clinical Oncology (126)
  2. American Association for Cancer Research (101)
  3. Oxford University Press (45)
  4. Elsevier Inc. (34)
  5. Nature Publishing Group (29)
  6. American Society of Hematology (23)

More Publishers

Results (461)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Camonsertib in DNA damage response-deficient advanced solid tumors: Phase 1 trial results
    Journal Article

    Yap, T. A.; Fontana, E.; Lee, E. K.; Spigel, D. R.; Højgaard, M.; Lheureux, S.; Mettu, N. B.; Carneiro, B. A.; Carter, L.; Plummer, R.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Avelumab plus talazoparib in patients with BRCA1/2- or ATM-altered advanced solid tumors: Results from JAVELIN BRCA/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial
    Journal Article

    Schram, A. M.; Colombo, N.; Arrowsmith, E.; Narayan, V.; Yonemori, K.; Scambia, G.; Zelnak, A.; Bauer, T. M.; Jin, N.; Ulahannan, S. V.; more...
    JAMA Oncology (2023)

    Fulltext@MSK | Save
  • Avelumab plus talazoparib in patients with advanced solid tumors: The JAVELIN PARP Medley nonrandomized controlled trial
    Journal Article

    Yap, T. A.; Bardia, A.; Dvorkin, M.; Galsky, M. D.; Beck, J. T.; Wise, D. R.; Karyakin, O.; Rubovszky, G.; Kislov, N.; Rohrberg, K.; more...
    JAMA Oncology (2023)

    Fulltext@MSK | Save
  • PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations
    Meeting Abstract

    Yap, T. A.; Im, S. A.; Schram, A. M.; Sharp, A.; Balmana, J.; Baird, R. D.; Brown, J. S.; Schwaederle, M.; Pilling, E. A.; Moorthy, G.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • OncoKB, MSK's precision oncology knowledge base
    Meeting Abstract

    Suehnholz, S. P.; Nissan, M.; Zhang, H.; Kundra, R.; Lu, C.; Dhaneshwar, A.; Fernandez, N.; Carrero, S.; Arcila, M. E.; Ladanyi, M.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
    Meeting Abstract

    Park, J. O.; Meng, D. T. W.; Hollebecque, A.; Borad, M.; Goyal, L.; Schram, A.; Cassier, P.; Kamath, S. D.; Dotan, E.; Kim, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
    Meeting Abstract

    Hollebecque, A.; Borad, M.; Goyal, L.; Schram, A.; Park, J. O.; Cassier, P. A.; Kamath, S. D.; Meng, D. T. W.; Dotan, E.; Kim, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Precision oncology: 2022 in review
    Review

    Rosen, E.; Drilon, A.; Chakravarty, D.
    Cancer Discovery (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers
    Meeting Abstract

    Schram, A. M.; Goto, K.; Kim, D. W.; Martin-Romano, P.; Ou, S. H. I.; O'Kane, G. M.; O'Reilly, E. M.; Umemoto, K.; Duruisseaux, M.; Neuzillet, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116)
    Meeting Abstract

    Rosen, E.; Silverman, I. M.; Fontana, E.; Lee, E. K.; Spigel, D. R.; Højgaard, M.; Lheureux, S.; Mettu, N. B.; Carneiro, B. A.; Carter, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save